MP71-08 FINASTERIDE DOES NOT PREVENT BLADDER CANCER: A SECONDARY ANALYSIS OF THE MEDICAL THERAPY FOR PROSTATIC SYMPTOMS STUDY

Abstract

You have accessJournal of UrologyBladder Cancer: Epidemiology & Evaluation II1 Apr 2018MP71-08 FINASTERIDE DOES NOT PREVENT BLADDER CANCER: A SECONDARY ANALYSIS OF THE MEDICAL THERAPY FOR PROSTATIC SYMPTOMS STUDY Niranjan Sathianathen, Yunhua Fan, Stephanie Jarosek, Nathan Lawrentschuk, and Badrinath Konety Niranjan SathianathenNiranjan Sathianathen More articles by this author , Yunhua FanYunhua Fan More articles by this author , Stephanie JarosekStephanie Jarosek More articles by this author , Nathan LawrentschukNathan Lawrentschuk More articles by this author , and Badrinath KonetyBadrinath Konety More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2272AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Pre-clinical models have demonstrated that androgen receptor modulation can influence bladder carcinogenesis with an association observed between serum androgen levels and bladder cancer incidence. Subsequently, it was hypothesised that finasteride could have a similar effect with a recent secondary analysis reporting a decreased cancer incidence amongst those taking the 5-reductase inhibitor. However, this analysis was based on self-reported finasteride use and did not account for dose or compliance. The current study aims to evaluate the impact of finasteride on bladder cancer incidence in a cohort of men included in a clinical trial of finasteride vs placebo with rigorous compliance monitoring. METHODS A secondary analysis was performed on all patients enrolled in the Medical Therapy for Prostatic Symptoms (MTOPS) Study and included in the biopsy sub-study. Men were stratified into groups based on receiving finasteride and the incidence of bladder cancer compared between the groups. Multivariate logistical regression analyses were performed to determine whether receiving finasteride was associated with bladder cancer incidence. RESULTS After exclusions for poor finasteride compliance (n=338) and missing serum hormone results (n=9), 2,700 men were eligible for analysis of which 1,029 participated in the biopsy substudy. Testosterone results were available for 62.9%(n=1,697) of the cohort. The overall incidence of bladder cancer was 0.8% (n=18). There was no difference in the incidence of bladder cancer between men who received finasteride and those who did not (1.08% vs 0.54%, p=0.48). There were 60 events of urinary retention of which none had bladder cancer (p=1.0). Similarly, 923 men had severe urinary symptoms as measured by IPSS but this did not differ between those who had bladder cancer and those who did not (33.3% vs 34.2%, p=0.94). There was no correlation between the incidence of prostate cancer between the groups (11.1% vs 7.3%, p=0.34). Neither receiving finasteride [OR 1.21, 95%CI 0.39-3.79, p=0.74], serum testosterone levels, prostate cancer diagnosis nor urinary symptoms acted as a significant predictor of bladder cancer diagnosis on multivariate regression analysis. These relationships were consistent in the subgroup of men in the biopsy substudy. CONCLUSIONS There was no observable relationship between finasteride use and bladder cancer diagnosis. This study is limited by the inability to adjust for confounders, such as smoking status, due to unavailability of data. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e946 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Niranjan Sathianathen More articles by this author Yunhua Fan More articles by this author Stephanie Jarosek More articles by this author Nathan Lawrentschuk More articles by this author Badrinath Konety More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...